Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Aligos Therapeutics (ALGS) Stock Drops -60% Amid Financing Concerns

Aligos Therapeutics (ALGS) Stock Drops -60% Amid Financing Concerns

Key Takeaways

  • ALGS shares fell roughly 60% over the last 30 days, sliding from about $5.23 to near $2.10 as of mid-November 2026.
  • The decline was driven primarily by a going-concern disclosure: management warned that its $31.1 million cash position funds operations only into the first quarter of 2027.
  • Third-quarter results showed a narrower net loss and an earnings beat, but the shrinking cash runway and looming financing needs overshadowed the operational progress.
  • Aligos completed enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium, with topline data not expected until late in the third quarter of 2027.
  • The stock has fallen roughly 69% over the last quarter, extending a longer-term downtrend from its 52-week highs.

Company Overview and Market Position

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company develops targeted therapies for liver and viral diseases, with a primary focus on chronic hepatitis B virus (CHB) infection, a large unmet medical need affecting hundreds of millions of people worldwide.

Its lead program is pevifoscorvir sodium, a small-molecule capsid assembly modulator (CAM-E) being evaluated as a potential best- or first-in-class treatment for CHB. The candidate has received FDA Fast Track Designation and is advancing through the Phase 2 B-SUPREME study. Aligos is also developing an antisense oligonucleotide candidate, ALG-170675, which has entered Phase 1 studies in China through its partnership with Amoytop. Because the company has no commercialized products, investors follow the stock for clinical data readouts, regulatory milestones, and the strength of its balance sheet rather than near-term revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ALGS shares have fallen approximately 60%, declining from around $5.23 in mid-October to about $2.10 in mid-November 2026. The move was not gradual: the stock traded in a relatively narrow range through most of October before a sharp sell-off in the first half of November, when the stock lost more than half of its value in a matter of days.

The last quarter tells a similar, if steeper, story. Roughly three months ago, shares were changing hands near $6.77, meaning the stock has declined close to 69% over that span. This quarterly decline extends a longer downtrend: ALGS traded well above $13 earlier in the year and has since moved toward the lower end of its 52-week range, reflecting sustained pressure on both the business and investor sentiment. From what I see, the pattern aligns with broader biotech volatility.

What Drove the Stock Price in the Last 30 Days

The most significant catalyst behind the recent decline was the company's third-quarter report, released in early November 2026. On the surface, the results contained positive elements: GAAP net loss narrowed to $21.9 million from $31.5 million a year earlier, revenue rose to roughly $2.8 million from $741,000, and the per-share loss of $(2.09) exceeded consensus expectations.

However, the accompanying disclosures dominated the market's reaction. In its quarterly filing, Aligos reported $31.1 million in cash, cash equivalents, and investments, down sharply from $77.8 million at the end of 2025, and stated that these resources are expected to fund operations only into the first quarter of 2027. Management also disclosed substantial doubt about its ability to continue as a going concern and indicated plans to raise additional capital. Because the pivotal B-SUPREME topline data is not expected until late in the third quarter of 2027, the financing gap is well ahead of the next major clinical catalyst, intensifying investor concerns about near-term dilution.

What Drove Stock Performance Over the Last Quarter

Over the last quarter, the broader narrative has been defined by the tension between clinical progress and a deteriorating balance sheet. Earlier in 2026, the stock had benefited from a series of positive developments, including the Amoytop licensing agreement with up to $420 million in potential milestone payments, FDA Fast Track Designation for pevifoscorvir sodium, and encouraging interim data from the Phase 2 B-SUPREME study.

Those catalysts were progressively outweighed by a steady decline in cash reserves and a data timeline that stretches further out than the company's available runway. Active financing instruments, including an at-the-market program and a shelf registration, added a persistent dilution overhang. As the cash position narrowed quarter over quarter, sentiment shifted from pipeline optimism toward financing risk, and the share price steadily gave back its earlier gains before the sharp November sell-off. I’m watching this closely as the dilution risk remains front and center.

ALGS Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term factor for ALGS is financing. Any announcement regarding a new capital raise, the use of its at-the-market facility, or restructuring of its cash runway will likely shape the stock's direction and determine the extent of shareholder dilution.

Beyond financing, investors should monitor the Phase 2 B-SUPREME study of pevifoscorvir sodium, with topline data anticipated in late third-quarter 2027, as well as progress of the ALG-170675 antisense oligonucleotide program in China. Additional milestone payments from the Amoytop partnership could also provide non-dilutive capital. Finally, broader conditions in the biotech financing market and sentiment toward clinical-stage small-cap companies will influence the company's ability to bridge its funding gap. These are informational factors to monitor, not a basis for investment decisions.

Exploring AI Tools in My Research Process

In my own research, I often turn to Tickeron’s AI Trading Bots to simulate different strategies on volatile names like this. The platform offers a range of options that can help gauge potential market reactions across hundreds of bots. It provides a practical way to explore automated approaches without replacing core fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALGS

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


Momentum Indicator for ALGS turns negative, indicating new downward trend

ALGS saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ALGS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.586). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
82
Web
https://www.aligos.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.